Evaluating the potential usefulness of new prognostic and predictive indicators on node-negative breast cancer patients

Journal of the National Cancer Institute

Volumn 85, Issue 15, 1993, Pages 1206-1219

  Gasparini, Giampietro ^a   Pozza, Franco ^a   Harris, Adrian L ^b  

^a Hospital St Bortolo   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; EVALUATION STUDIES; HUMAN; LYMPHATIC METASTASIS; MALE; MIDDLE AGE; PROGNOSIS; RISK; SUPPORT, NON-U.S. GOV'T; TUMOR MARKERS, BIOLOGICAL;

EID: 0027235762     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.15.1206     Document Type: Review

References (164)

1. Borino CC, Squires TS, Tono T: Cancer statistics, 1992. CA Cancer J Clin 42:19-38, 1992
2. National Center for Health Statistics: Vital statistics of the United States, 1987. vol. 2. Mortality. Part A. Washington, DC: US Gov Print Off DHHS Publ No. (PHS) 90-1101, 1990
3. Reynolds T, Ries LAG: Breast cancer deaths in American women, Ages 40-44. J Natl Cancer Inst 84: 663, 1992
4. Miller BA, Feuer EJ, Hankey BF: The increasing incidence of breast cancer since 1982: Relevance of early detection. Cancer Causes Control 2:67-74, 1991
5. Fisher B, Redmond C, Dimitrov NV, et al A randomized controlled trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473-478, 1989
6. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 320:485-490, 1989
7. The Ludwing Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
8. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-positive tumors. N Engl J Med 320:479-484, 1989
9. Bonadonna G, Valacussa P: Role of chemotherapy in stage I breast cancer. In Important Advances in Oncology 1989. (De Vita VT Jr, Heilman S, Rosenberg SA, eds). Philadelphia: Lippincott, 1989, pp 151-160
10. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
11. Dexter DL, Kowalsky HM, Blazer BA, et al: Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38:3174-3181, 1978
12. Osborne CK: Prognostic factors for breast cancer: Have they met their promise? J Clin Oncol 10:679-682, 1992
13. enderson Cl: Breast cancer therapy. The price of success. N Engl J Med 326:1774-1775, 1992
14. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer patients. N Engl J Med 326:1756-1761, 1992
15. Fentiman IS, Mansel RE: The axilla: Not a no-go zone. Lancet 337:221-223, 1991
16. Veronesi U, Luini A, Galimberti V, et al: Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 16:127-133, 1990
17. Kissin MW, Thompson EM, Price AB, et al: The inadequacy of axillary sampling in breast cancer. Lancet 1:1210-1212, 1982
18. Henderson IC Prognostic factors. In Breast Disease (Harris JR, Heilman S, Henderson IC, et al, eds), 2nd ed. Philadelphia: Lippincott, 1991, pp 332-346
19. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 109:219-228, 1988
20. Nolvadex Adjuvant Trial Organization (NATO): Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at eight years. Br J Cancer 57:608-611, 1988
21. Steward HJ: The Scottish trial of adjuvant tamoxifen in nodenegative breast cancer. The Scottish Cancer Trials Breast Group. Monogr Natl Cancer Inst 11:117-120, 1992
22. Nicholson S, Sainsbury JRC, Halcrow P, et al: Expression of epidermal growth factor receptor associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1:182-185, 1989
23. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
24. Gasparini G, Gullick WJ, Bevilacqua P, et al: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992
25. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
26. Mittra I, MacRae KD: A meta-analysis of reported correlations between prognostic factors in breast cancer: Does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 27:1574-1583, 1991
27. Spyratos F, Martin PM, HacEne K, et al: Multiparamelric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992
28. Nemoto T, Vana J, BedwaniRN, et al: Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45:2917-2924, 1989
29. Carter CL, Allen C, Henson DE: Relationship of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181-187, 1989
30. Adair F, Berg J, Joubert L, et al: Long term follow-up of breast cancer patients: The 30 year report. Cancer 33:1145-1150, 1974
31. Rosen PP, Groshen S, Saigo PE, et al: Pathological prognostic factors in Stage I (TiNqMo) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239-1251, 1989
32. Rosen PP, Saigo PE, Braun DW Jr., et al: Predictors of recurrence in Stage 1 (TiNqMq) breast carcinoma. Ann Surg 193:15-25, 1981
33. Fisher ER, Gregorio RM, Fisher B: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36:1-85, 1975
34. BloomHG, Richardson WW: Histological grading and prognosis. Br J Cancer 11:359-377, 1957
35. Le Doussal V, Tubiana-Hulin M, Friedman S, et al: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinoma. Cancer 64:1914-1921, 1989
36. Fisher ER, Redmond C, Fisher B, et al: Prognostic factors in NSABP studies of women with node-negative breast cancer. Monogr Natl Cancer Inst 11:151-158, 1992
37. Contesso G, Jotti G, Bonadonna G-Tumour grade as a prognostic factor in primary breast cancer. Eur J Cancer Clin Oncol 25:403-409, 1989
38. Marx J: Cellular changes on the route to metastasis. Science 259:626-629, 1993
39. Lee AK, De Lellis RA, Silverman ML, et al: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8:1457-1465, 1990
40. Gasparini G, Meli S, Panizzoni GA, et al: Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Treat 20:195-204, 1991
41. Clemente CG, Boracchi P, Andreola S, et al: Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 69:1396-1403, 1992
42. Simpson JF, Page DL: Prognostic value of histopathology in the breast. Semin Oncol 19:254-262, 1992
43. Baker RR: Unusual lesions and their management. Surg Clin North Am 70 963-975, 1990
44. Komari K, Sakamoto G,: Mucinous carcinoma of the breast in Japan: A prognostic analysis based on morphologic features. Cancer 61:989-996, 1988
45. Fisher B, et al: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076-1087, 1988
46. Alleora JC, Lippman ME, Simon R, et al: Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63:1271-1277, 1979
47. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44:671-675, 1979
48. Kinne DW, Ashikari R, Butler A, et al: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47:2364-2367, 1981
49. Williams MR, Nicholson RI, Elston CW, et al: Oestrogen receptors in primary breast cancer. Br J Cancer 51:907-909, 1985
50. McGuire WL: Estrogen receptor versus nuclear grade as prognostic factors in axillary node negative breast cancer. J Clin Oncol 6:1071-1072, 1988
51. Kohail HM, Elias EG, El-Nowiem SA, et al: A multifactorial analysis of steroid hormone receptors in stages I and II breast cancer. Ann Surg 201:611-617, 1985
52. Chevalier B, Heintzmann F, Mosseri V, et al: Prognostic value of estrogen and progesterone receptors in operable breast cancer. Cancer 62:2517-2524, 1988
53. Mason BH, Holdaway IM,: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43:2985-2990, 1983
54. Reiner A, Neumeister B, Spona J, et al: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50:7057-7061, 1990
55. Pertschuk LP, Kim DS, Nayer K, et al: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationships to endocrine response and survival. Cancer 66:1663-1670, 1990
56. Gasparini G, et al: Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer. J Cancer Res Clin Oncol 118:557-563, 1992
57. Sainsbury JR, Farndon JR, Needham GK, et al: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 20:1398-1402, 1987
58. Macias A, Azavedo E, Hagerstrom T, et al: Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res 7:459-464, 1987
59. Tot M, Osaki A, Yamada H, et al: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977-980, 1991
60. Nicholson S, Richard J, Sainsbury C, et al: Epidermal growth factor receptor (EGFr); Results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146-150, 1991
61. Gasparini G, Bevilacqua P, Pozza F, et al: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970-976, 1992
62. Foekens JA, Portenoen H, van Putten WLJ, et al: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989
63. Spyratos F, Delarue JC, Andrieu C, et al: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17:83-89, 1990
64. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
65. Paterson MC, Dietrich KD, Kanyluk J, et al: Correlation between c-erbB-2 amplification and nsk of recurrent disease in nodenegative breast cancer. Cancer Res 51:556-567, 1991
66. Gullick WJ, Love SB, c-erbB-2 Protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438, 1991
67. Winstanley J, Cooke T, Murray GD, et al: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447-50, 1991
68. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in nodenegative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:559-605, 1992
69. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
70. Tandon AK, Clark GM, Chamness GC, et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
71. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
72. Lovekin C, Ellis IO, Locker A, et al: c-erbB-2 Oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
73. Thor AD, Schwartz LH, Koerner FC, et al: Analysis of c-erbB-2 expression in breast carcinoma with clinical follow-up. Cancer Res 49:7147-7152, 1989
74. Clair T, Miller WR, Cho-Chuno YS: Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 47:5290-5293, 1987
75. Cline MJ, Battifora H, Yokota J: Proto-oncogene abnormalities in human breast cancer: Correlations with anatomic features and clinical course of disease. J Clin Oncol 5:999-1006, 1987
76. Watson DM, Elton RA, Jack WJ, et al: The H-ras oncogene product p2I and prognosis in human breast cancer. Breast Cancer Res Treat 17:161-169, 1990
77. Gu6rin M, Barrois M, Rtou G: C-myb proto-oncogene expression in breast cancer: Strong association with estrogen receptors. Proc Am Assoc Cancer Res 30:439, 1989
78. Bonneterre J, Peyrat JP, Beuscart R, et al: Prognostic significance of IGF1 receptors (IGF1-R) in human breast cancer. Breast Cancer Res Treat 14:166, 1989
79. Berns EMJJ, Klijn JGM, van Staveren IL, et al: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 52:1036-1039, 1992
80. Colston KW, Berger U, Coombes RC Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1:188-191, 1989
81. Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56:1982-1987, 1985
82. Silvestrini R, Daidone MG, Di Fronzo G, et al: Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res Treat 7:161-169, 1986
83. Meyer JS: Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma. Monogr Natl Cancer Inst 1:2528, 1986
84. Tubiana M, Pejovic MH, Koscielny S, et al: Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 4417-22, 1989
85. Meyer JS, Friedman E, McCrate MM, et al: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51:, 1983
86. McDivitt RW, et al: A proposed classification of breast cancer based on kinetic information Cancer 57:269-276, 1986
87. Hery M, Gioanni J, Lalanne CM, et al: The DNA labelling index: A prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9:207-211, 1987
88. Hedley DW, Ruoo CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of node positive early breast cancer. Cancer Res 47:4729-4735, 1987
89. Kallioniemi OP, Blanco G, Alavaikko M, et al: Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer 62 2183-2190, 1988
90. Clark GM, Dressler LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
91. Lykkesfeldt AE, Balslev I, Christensen J, et al DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease. Acta Oncol 27:749-756, 1988
92. McGuire WL,: Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. JNCI 75:405-410, 1985
93. Gasparini G, Pozza F, Bevilacqua P, et al: Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: Histologic, clinical and prognostic correlations. The Breast 1:92-99, 1992
94. Sahin AA, Ro J, Ro JY, et al: Ki-67 immunostaining in nodenegative stage 1/11 breast carcinoma. Significant correlation with prognosis. Cancer 68:549-557, 1991
95. Bouzubar N, Walker KJ, Griffiths K, et al: Ki67 immunostaining in primary breast cancer: Pathological and clinical associations. Br J Cancer 59:943-947, 1989
96. Weikel W, Beck T, Mitze M, et al: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18:149-154, 1991
97. WlNTZER HO, ET AL: Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 67:421-428, 1991
98. Weidner N, Semple JP, Welch WT, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
99. Bosari S, Lee AKC, De Lellis RA, et al: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
100. Kaldjian E, Jin L, Lloyd R: Immunohistochemical analysis of breast carcinomas: Correlation of estrogen and progesterone receptors, proliferative activity, tumor vascularity, and lymph node metastasis. Mod Pathol 5:14, 1992
101. Sneige N, Singletary E, et al: Multiparameter analysis of potential prognostic factors in node negative breast cancer patients. Mod Pathol 5:18. 1992
102. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastasis and survival in breast cancer. Lancet 340:1120-1124, 1992
103. Hennessy C, et al: Expression of the antimetastatic gene nm 23 in human breast cancer: An association with good prognosis. J Natl Cancer Inst 83:281-285, 1991
104. Steed PS, Bevilacqua G, Kopper L, et al: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80:200-204, 1988
105. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
106. Ostrowski JL, Wright C, et al: p53 Expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol 164:75-81, 1991
107. Isola J, Visakorpi T, Holli K, et al: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
108. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
109. Thorpe SM, Rochefort H, Garcia M, et al: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49:6008-6014, 1989
110. Spyratos F, Maudelonde T, Brouillet JP, et al: Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet 8672:1115-1118, 1989
111. Tandon A, Clark G, Chirgwin J, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990
112. Namer M, Ramaioli A, Fontana X, et al: Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat 19:85-93, 1991
113. Gasparini G, et al: Immunocytochemical determination of pro-cathepsin D: a significant and independent prognostic indicator in early-stage breast cancer. Breast Dis 6:85-97, 1993
114. Isola J, Weitz S, Visakorpi T, et al: Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 11:36-43, 1993
115. Thor A, Benz C, Moore D, et al: Stress response protein (srp-27) determination in primary human breast carcinomas: Clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83:170-178, 1991
116. Chamnes GC, Ruiz A, Fulcher L, et al: Estrogen-inducible heat shock protein hsp27 predicts recurrence in node negative breast cancer. Proc Am Assoc Cancer Res 30:252, 1989
117. Tandon AK, Clark GM, Chamness GC, et al: Clinical significance of heat-shock/stress-response proteins in breast cancer. Breast Cancer Res Treat 16:146, 1990
118. Duffy MJ, O’Grady P, Devaney D, et al: Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48:1348-1349, 1988
119. Martignone S, MSnard S, Bufalino R, et al: Prognostic significance of the 67-ktlodalton laminin receptor expression in human breast carcinomas. J Natl Cancer Inst 85:398-402, 1993
120. Hedley DW, Ruoo CA, Ng ABP, et al: Influence of cellular DNA content on disease-free survival of stage II breast cancer patients. Cancer Res 44:5395-5398, 1984
121. Cornelisse CJ, van de Velde CJH, Caspers RJC, et al' DNA ploidy and survival in breast cancer patients. Cytometry 8:225-234, 1987
122. von Rosen A, Rutqvist LE, Carstensen J, et al: Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content. Breast Cancer Res Treast 13:23-32, 1989
123. Coulson PB, Thornthwaite JT. Woolley TW, et al: Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival. Cancer Res 44:4187-4196, 1984
124. Fallenius AG, Auer GU, Carstensen JM: Prognostic significance of DNA measurements in 409 consecutive breast cancer patients. Cancer 62:331-341, 1988
125. Bieche I, Champeme MH, et al: Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1:139-143, 1992
126. Hainsworth PJ, Raphael KL, Stillwell RG, et al: Rearrangement of chromosome lp in breast cancer correlates with poor prognostic features. Br J Cancer 66:131-135, 1992
127. Kuhajda FP, Piantadosi S, Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636-641, 1989
128. Foekens JA, Put-ten WLJ, Portenoen H, et al: Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: mutivariate analysis. J Clin Oncol 11:899-908, 1993
129. Predine J, et al: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer 69:2116-2123, 1992
130. Senie RT, et al: Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 115 337-342, 1991
131. Hrushesky WJ, Bluming AZ, Gruber SA, et al: Menstrual influence on surgical cure of breast cancer. Lancet 2:949-952, 1989
132. Regeth JC, Wyss P, Unger C, et al: Timing of breast cancer surgery within the menstrual cycle: influence on lymph-node involvement, receptor status, postoperative metastatic spread and local recurrence. Ann Oncol 2:269-272, 1991
133. Badwe RA, Gregory WM, Chavadary MA, et al: Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 2:1261-1264, 1991
134. Wright C, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
135. Look AT, Hayes A, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311 231-235, 1984
136. Dressler LG, Eudey L, Gray R, et al: DNA flow cytometry measurements are prognostic for time to recurrence in node negative breast cancer patients. An ECOG Intergroup Study. Proc Am Soc Clin Oncol 9:22, 1990
137. Silvestrini R, Daidone MG, et al: Cell kinetics as a prognostic marker in locally advanced breast cancer. Cancer Treat Rep 71:375-379, 1987
138. Ciocca DR, Fuqua SAW, Lock-Lim S, et al: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52:3648-3654, 1992
139. Wright C, Cairns J, et al: Response to mitoxantrone in advanced breast cancer: Correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer 65:271-274, 1992
140. Gasparini G, et al: P-glycoprotein expression predicts response to chemotherapy in previously untreated stage III and IV breast cancer. The Breast 2:27-32, 1993
141. Ro J, Sahin A, et al: Immunocytochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol 21:787-791, 1990
142. Verrelle P, Meissonnier F, Fonk Y, et al-Clinical relevance of immunohistochemical detection of multidrug resistance P-glycopro-tein in breast carcinoma. J Natl Cancer Inst 83:111-116, 1991
143. Lippman ME: The development of biological therapies for breast cancer. Science 259:631-632, 1993
144. Workman P, DTncalci M, Berdel WE, et al: New approaches in cancer pharmacology: drug design and development. Eur J Cancer 28A: 1190-1200, 1992
145. Jones PA, Norris K: Fourth Charles Heidelberger Conference on transformation and chemotherapy. Cancer Res 52:3821-3825, 1992
146. Folkman J, Klaosbrun M: Angiogenic factors. Science 235:442447, 1987
147. Watanabe H, Hori A, Seno M, et al: A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 175:229-235, 1991
148. Nguyen M, Watanabe H, Budson A, et al: Basic fibroblast growth factor (bFGF) is elevated in the urine of patients with a wide variety of neoplasms. Mol Biol Cell 3:234, 1992
149. Li V, Yu C, Rupnick R, et al: Serum from breast cancer patients contains proliferative activity for capillary endothelial cells which correlates with risk of mortality. Proc Am Soc Clin Oncol 12:252, 1993
150. Leonard RC: Tumor markers of prognosis. J Clin Oncol 9:1102-1104, 1991
151. Kinsel LB, Szabo E, Greene GL, et al: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 49:1052-1056, 1989
152. Rocheford H: Cathepsin D in breast cancer: A tissue marker associated with metastasis. Eur J Cancer. 28A: 1780-1783, 1992
153. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
154. Consensus statement: Treatment of early-stage breast cancer. National Institutes of Health Consensus Development Panel. Monogr Natl Cancer Inst 11:1-5, 1992
155. Sackett DL: Bias in analytic research. J Chronic Dis 32:51-63, 1979
156. Levine MN, Andrulis I: The Her-2/neu oncogene in breast cancer: So what is new? J Clin Oncol 10:1034-1036, 1992
157. Gasparini G, Boracchi P, Bevilacqua P, et al: Multiparametric analysis of the prognostic value of epidermal growth factor receptor in operable brest carcinomas. Breast Cancer Res Treat. In press
158. Sparano JA, O’Boyle K: The potential role for biological therapy in the treatment of breast cancer. Semin Oncol 19:333-341, 1992
159. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990
160. Fisher B, Gunduz N, Constantino J, et al: DNA flow cytometric analysis of primary operable breast cancer: Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 68:1465-1475, 1991
161. Chin K-V, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255:459-462, 1992
162. Zastawny RL, Salvino R, Chen J, et al: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8:1529-1535, 1993
163. Harris AL, Nicholson S, Sainsbury JR, et al: Epidermal growth factor receptor and other oncogenes as prognostic markers. Monogr Natl Cancer Inst 11:181-187, 1992
164. Hochhauser D, Harris AL: The role of topoisomerase Ila and 3 in drug resistance. Cancer Treat Rev 19:181-194, 1993